Smith D M, Groff D E, Pokul R K, Bear J L, Delgado G
Division of Gynecologic Oncology, Georgetown University Medical Center.
Am J Obstet Gynecol. 1989 Oct;161(4):911-5. doi: 10.1016/0002-9378(89)90750-3.
Four cellular oncogenes, fos, myc, Ha-ras, and Ki-ras, are routinely expressed in ovarian adenocarcinomas. To determine whether the molecular lesion in ovarian carcinoma was a genetic rearrangement or amplification of expressed oncogenes, we examined the myc, Ha-ras, Ki-ras, and fos oncogenes in 14 serous adenocarcinomas of the ovary using molecular hybridization techniques. Using a series of diagnostic restriction endonucleases and gene-specific deoxyribonucleic acid probes, we found no evidence of rearrangement of these genes. In addition, we found no evidence of amplification of the cellular oncogenes analyzed in this series of ovarian tumors. Therefore genetic rearrangement or amplification of these cellular oncogenes is not the primary molecular lesion leading to their expression in ovarian carcinomas.
四种细胞癌基因,即fos、myc、Ha-ras和Ki-ras,在卵巢腺癌中经常表达。为了确定卵巢癌中的分子病变是表达的癌基因发生了基因重排还是扩增,我们使用分子杂交技术检测了14例卵巢浆液性腺癌中的myc、Ha-ras、Ki-ras和fos癌基因。通过一系列诊断性限制性内切酶和基因特异性脱氧核糖核酸探针,我们没有发现这些基因重排的证据。此外,在这一系列卵巢肿瘤中,我们也没有发现所分析的细胞癌基因发生扩增的证据。因此,这些细胞癌基因的基因重排或扩增并非导致它们在卵巢癌中表达的主要分子病变。